PMID- 32293696
OWN - NLM
STAT- MEDLINE
DCOM- 20210813
LR  - 20210813
IS  - 1699-5848 (Electronic)
IS  - 0213-3911 (Linking)
VI  - 35
IP  - 9
DP  - 2020 Sep
TI  - Solid phase-based cross-matching for solid organ transplantation: Currently 
      out-of-stock but urgently required for improved allograft outcome.
PG  - 937-948
LID - 10.14670/HH-18-217 [doi]
AB  - Transplant recipients who have undergone sensitizing events, such as pregnancy, 
      blood transfusion or previous transplants, frequently develop antibodies directed 
      against the highly polymorphous human leukocyte antigen (HLA)-molecules. These 
      pre-formed, donor-specific antibodies (DSA) present a high risk of causing organ 
      failure or even complete loss of the grafted organ as a consequence of 
      antibody-mediated, hyper-acute or acute allograft rejection. In order to detect 
      DSA, the so-called functional complement-dependent lymphocytotoxicity assay 
      (CDC-XM) was established about 50 years ago. Although effective in improving the 
      outcome of solid organ allo-grafting, for the last ten years this assay has been 
      controversially discussed due to its low sensitivity and especially because of 
      its high susceptibility to various artificial factors, which generally do not 
      yield reliable results. As a consequence, novel immunochemical test systems have 
      been developed using ELISA- or bead-based solid phase assays as replacements for 
      the traditional CDC-based assays. Because these assays are independent of single 
      or vital cells, which are frequently not available, they have provided an 
      additional and alternative diagnostic approach compared with the traditional 
      CDC-based and flow-cytometric analyses. Unfortunately, however, the AMS-ELISA 
      (Antibody Monitoring System), which was the first system to become commercially 
      available, was recently discontinued by the manufacturer after seven years of 
      successful use. Alternative procedures, such as the AbCross-ELISA, had to be 
      either considerably modified, or did not yield reliable results, as in the case 
      of the Luminex-based assay termed DSA. We draw the conclusion that due to the 
      unique features and fields of application reviewed here, the implementation of 
      solid phase cross-matching still represents an urgent requirement for any 
      HLA-laboratory's routine tasks.
FAU - Schlaf, Gerald
AU  - Schlaf G
AD  - Tissue Typing Laboratory (GHATT), University Hospital, Martin-Luther University 
      Halle-Wittenberg, Germany. gerald.schlaf@uk-halle.de.
FAU - Bau, Daniela
AU  - Bau D
AD  - Tissue Typing Laboratory (GHATT), University Hospital, Martin-Luther University 
      Halle-Wittenberg, Germany.
FAU - Horstmann, Nathalie
AU  - Horstmann N
AD  - Tissue Typing Laboratory (GHATT), University Hospital, Martin-Luther University 
      Halle-Wittenberg, Germany.
FAU - Sawers, Gary
AU  - Sawers G
AD  - Institute of Biology/Microbiology, Martin-Luther University Halle-Wittenberg, 
      Germany.
FAU - Altermann, Wolfgang
AU  - Altermann W
AD  - Tissue Typing Laboratory (GHATT), University Hospital, Martin-Luther University 
      Halle-Wittenberg, Germany.
LA  - eng
GR  - -/-/
PT  - Journal Article
PT  - Review
DEP - 20200415
PL  - Spain
TA  - Histol Histopathol
JT  - Histology and histopathology
JID - 8609357
RN  - 0 (HLA Antigens)
SB  - IM
MH  - *Allografts
MH  - Donor Selection
MH  - Graft Rejection/immunology/*prevention & control
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Organ Transplantation/*methods
EDAT- 2020/04/16 06:00
MHDA- 2021/08/14 06:00
CRDT- 2020/04/16 06:00
PHST- 2020/04/16 06:00 [pubmed]
PHST- 2021/08/14 06:00 [medline]
PHST- 2020/04/16 06:00 [entrez]
AID - HH-18-217 [pii]
AID - 10.14670/HH-18-217 [doi]
PST - ppublish
SO  - Histol Histopathol. 2020 Sep;35(9):937-948. doi: 10.14670/HH-18-217. Epub 2020 
      Apr 15.